Claret Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.6M | Sell |
113,664
-1,643
| -1% | -$353K | 3.08% | 6 |
|
|
2026
Q1 | $25.1M | Sell |
115,307
-1,588
| -1% | -$352K | 3% | 8 |
|
|
2025
Q4 | $26.7M | Sell |
116,895
-1,985
| -2% | -$452K | 3.1% | 9 |
|
|
2025
Q3 | $27.5M | Sell |
118,880
-3,800
| -3% | -$774K | 3.28% | 10 |
|
|
2025
Q2 | $22.8M | Sell |
122,680
-835
| -0.7% | -$155K | 2.95% | 11 |
|
|
2025
Q1 | $25.9M | Sell |
123,515
-4,301
| -3% | -$836K | 3.73% | 7 |
|
|
2024
Q4 | $22.7M | Sell |
127,816
-2,817
| -2% | -$518K | 3.59% | 9 |
|
|
2024
Q3 | $25.8M | Sell |
130,633
-3,601
| -3% | -$672K | 4.22% | 5 |
|
|
2024
Q2 | $23M | Sell |
134,234
-5,875
| -4% | -$973K | 4.1% | 8 |
|
|
2024
Q1 | $25.5M | Sell |
140,109
-2,181
| -2% | -$376K | 4.29% | 5 |
|
|
2023
Q4 | $22.1M | Sell |
142,290
-468
| -0.3% | -$68.2K | 3.94% | 9 |
|
|
2023
Q3 | $21.3M | Sell |
142,758
-1,376
| -1% | -$202K | 4.18% | 7 |
|
|
2023
Q2 | $19.4M | Sell |
144,134
-1,021
| -0.7% | -$150K | 3.79% | 6 |
|
|
2023
Q1 | $23.1M | Sell |
145,155
-2,123
| -1% | -$325K | 4.57% | 4 |
|
|
2022
Q4 | $23.8M | Sell |
147,278
-453
| -0.3% | -$69.5K | 5.26% | 3 |
|
|
2022
Q3 | $19.8M | Sell |
147,731
-2,052
| -1% | -$294K | 4.7% | 4 |
|
|
2022
Q2 | $22.9M | Sell |
149,783
-6,263
| -4% | -$957K | 4.95% | 3 |
|
|
2022
Q1 | $25.3M | Sell |
156,046
-12,428
| -7% | -$1.81M | 4.86% | 3 |
|
|
2021
Q4 | $22.8M | Sell |
168,474
-421
| -0.2% | -$49.7K | 4.22% | 4 |
|
|
2021
Q3 | $18.2M | Buy |
168,895
+11,511
| +7% | +$1.32M | 3.12% | 8 |
|
|
2021
Q2 | $17.7M | Buy |
157,384
+10,455
| +7% | +$1.18M | 2.91% | 8 |
|
|
2021
Q1 | $15.9M | Sell |
146,929
-1,035
| -0.7% | -$111K | 2.95% | 11 |
|
|
2020
Q4 | $15.9M | Buy |
147,964
+12,716
| +9% | +$1.22M | 3.13% | 9 |
|
|
2020
Q3 | $11.8M | Sell |
135,248
-1,037
| -0.8% | -$97.6K | 2.64% | 12 |
|
|
2020
Q2 | $13.4M | Sell |
136,285
-4,223
| -3% | -$372K | 3.17% | 9 |
|
|
2020
Q1 | $10.7M | Sell |
140,508
-6,109
| -4% | -$520K | 3.02% | 8 |
|
|
2019
Q4 | $13M | Sell |
146,617
-601
| -0.4% | -$49.9K | 2.49% | 10 |
|
|
2019
Q3 | $11.1M | Buy |
147,218
+518
| +0.4% | +$35.5K | 2.29% | 9 |
|
|
2019
Q2 | $10.7M | Sell |
146,700
-1,219
| -0.8% | -$95.8K | 2.21% | 10 |
|
|
2019
Q1 | $11.9M | Sell |
147,919
-280
| -0.2% | -$22.9K | 2.37% | 7 |
|
|
2018
Q4 | $13.7M | Sell |
148,199
-5,654
| -4% | -$497K | 3.04% | 7 |
|
|
2018
Q3 | $14.6M | Buy |
153,853
+3,231
| +2% | +$306K | 2.8% | 8 |
|
|
2018
Q2 | $14M | Buy |
150,622
+2,399
| +2% | +$234K | 2.85% | 7 |
|
|
2018
Q1 | $14M | Sell |
148,223
-10,264
| -6% | -$1.13M | 3.19% | 5 |
|
|
2017
Q4 | $15.3M | Buy |
+158,487
| New | +$14.9M | 3.34% | 4 |
|
Other funds holding ABBV
Claret Asset Management's ABBV Position: Q2 2026 in Review
Claret Asset Management reduced its AbbVie (ABBV) stake by 1.4% in Q2 2026, selling an estimated $353K and leaving 113,664 shares worth $28.6M. The position accounts for 3.08% of the portfolio, ranked #6.
Claret Asset Management first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Claret Asset Management held 113,664 shares of AbbVie worth $28.6M as of Q2 2026.
- Claret Asset Management sold 1,643 AbbVie shares in Q2 2026, an estimated $353K.
- AbbVie made up 3.08% of Claret Asset Management's portfolio in Q2 2026, its #6 holding.
- Claret Asset Management first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.